- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03898414
Patterns and Outcome of Autoimmune Related Liver Disease
Patterns and Outcome of Autoimmune Related Chronic Liver Disease : Retrospective Study
Study Overview
Status
Conditions
Detailed Description
Autoimmune liver diseases (AILD) are a group of immunologically induced hepatic damage that are either hepatocellular or cholestatic. The hepatocellular forms are characterized by a significant elevation of the serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST), as compared with the biliary enzymes,together with elevated serum bilirubin Autoimmune hepatitis (AIH) is the typical example of hepatocellular autoimmune liver diseases, but it can also be presented under a cholestatic pattern. Autoimmune hepatitis has a scoring diagnostic system and respond in most cases to the treatment with prednisolone and azathioprine. Primary biliary cirrhosis (PBC) is the second most common autoimmune liver diseases , with a cholestatic presentation and characterized by positive antimitochondrial antibody (AMA). It has an excellent response and long term outcome with the administration of ursodeoxycholic acid (UDCA) Another autoimmune liver disease that is thought to be a variant of PBC is the autoimmune cholangitis, being a disease that has biochemical and histological features similar to PBC; but the AMA is negative. Primary sclerosing cholangitis (PSC) is a rare entity of autoimmune liver disease that has a cholestatic presentation and respond poorly to the treatment, with the ultimate progression to advance liver cirrhosis in most patients Other forms of autoimmune liver disease include the overlap syndromes (OS), which are diseases with mixed immunological and histological patterns of two autoimmune liver disease the most commonly recognized one is AIH-PBC overlap (AIH-PSC overlap is less common). The treatment of OS involves the trial of ursodeoxycholic acid and different immunosuppressant.
The vast majority of studies examining the incidence and prevalence of autoimmune liver disease have focused on PBC. Estimates of both disease incidence and prevalence vary quite widely between studies of specific defined populations.
Primary biliary cirrhosis (PBC), autoimmune hepatitis (AIH) and primary sclerosing cholangitis (PSC) are chronic liver diseases that likely have an autoimmune basis to their pathogenesis. Although significant strides have been made in the clinical management of these conditions, their pathogenesis remains obscure. Understanding of various epidemiological factors may shed light on predisposing or causative factors of these diseases There are limited Egyptian studies available on prevalence and spectrum of autoimmune liver diseases in cholestatic liver diseases, so the investigators will design this work to evaluate the prevalence of autoimmune liver diseases in cholestatic liver diseases and clinical profile of the various autoimmune liver diseases.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Assiut, Egypt
- Assiut university hospitals
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
-Inclusion criteria :
Patients that will fulfill the following criteria will be enrolled:
- Patients diagnosed as AIH According to the simplified criteria of AIH scoring
- Patients diagnosed as PBC or PSC according to the Amiracan association of study of liver disease (AASLD) - For all enrolled patients the presentation, treatment history, and outcome of treatment will be evaluated.
Exclusion criteria :
1-- All patients with chronic liver disease other than autoimmune liver disease will be excluded
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluation of patterns of autoimmune chronic liver diseases
Time Frame: 2013-2019
|
Evaluation of patterns of autoimmune chronic liver diseasesupport and outcome of treagent of these diseases
|
2013-2019
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Yomna Abou Elwafa, Assiut University
- Study Director: Adnan Mohamed, Lecturer, Assiut University
- Study Director: Mohamed Mekky, Ass. Prof., Assiut University
Publications and helpful links
General Publications
- Lee YM, Teo EK, Ng TM, Khor C, Fock KM. Autoimmune hepatitis in Singapore: a rare syndrome affecting middle-aged women. J Gastroenterol Hepatol. 2001 Dec;16(12):1384-9. doi: 10.1046/j.1440-1746.2001.02646.x.
- Floreani A, Niro G, Rosa Rizzotto E, Antoniazzi S, Ferrara F, Carderi I, Baldo V, Premoli A, Olivero F, Morello E, Durazzo M. Type I autoimmune hepatitis: clinical course and outcome in an Italian multicentre study. Aliment Pharmacol Ther. 2006 Oct 1;24(7):1051-7. doi: 10.1111/j.1365-2036.2006.03104.x.
- Kumagi T, Alswat K, Hirschfield GM, Heathcote J. New insights into autoimmune liver diseases. Hepatol Res. 2008 Aug;38(8):745-61. doi: 10.1111/j.1872-034X.2008.00366.x. Epub 2008 May 7.
- Fallatah HI, Akbar HO, Qari YA. Autoimmune hepatitis: Single-center experience of clinical presentation, response to treatment and prognosis in Saudi Arabia. Saudi J Gastroenterol. 2010 Apr-Jun;16(2):95-9. doi: 10.4103/1319-3767.61235.
- Hirschfield GM, Al-Harthi N, Heathcote EJ. Current status of therapy in autoimmune liver disease. Therap Adv Gastroenterol. 2009 Jan;2(1):11-28. doi: 10.1177/1756283X08098966.
- Bogdanos DP, Gershwin ME. What is new in primary biliary cirrhosis? Dig Dis. 2012;30 Suppl 1:20-31. doi: 10.1159/000341118. Epub 2012 Oct 11.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- autoimmune liver disease
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Autoimmune Liver Disease
-
Beijing Ditan HospitalCompleted
-
Hannover Medical SchoolRecruitingAutoimmune Liver Disease | Autoimmune HepatitisGermany
-
PerspectumChildren's Memorial Health Institute, PolandCompletedLiver Diseases | Autoimmune Hepatitis | Liver Cirrhoses | Non-alcoholic Steatohepatitis | Liver FibrosesPoland
-
Children's Hospital Medical Center, CincinnatiRecruitingAutoimmune Liver Disease | Primary Sclerosing Cholangitis | Autoimmune HepatitisUnited States
-
Children's Hospital Medical Center, CincinnatiRecruitingAutoimmune Liver Disease | Primary Sclerosing Cholangitis | Autoimmune HepatitisUnited States
-
Northwestern UniversityIcahn School of Medicine at Mount Sinai; Mount Sinai Hospital, New YorkCompletedAutoimmune HepatitisUnited States
-
Washington University School of MedicineTransplant Genomics, Inc.Not yet recruitingAutoimmune Liver Disease | Primary Sclerosing Cholangitis | Autoimmune Hepatitis | Primary Biliary Cirrhosis
-
Institute of Liver and Biliary Sciences, IndiaNot yet recruitingAutoimmune DiseasesIndia
-
University Health Network, TorontoRecruitingAutoimmune Hepatitis | Primary Bilary Cirrhosis (PBC) | Overlap SyndromeCanada
-
The Second Affiliated Hospital of Chongqing Medical...Not yet recruitingAutoimmune Diseases | Healthy | Chronic Liver Disease | Malignant Tumor